Goldberg, MD, discusses 5-year outcomes of pegcetacoplan for the treatment of geographic atrophy. Data from the GALE ...

Geographic atrophy is a subtype of advanced age-related macular degeneration (AMD). It causes blind spots in the center of vision and a permanent loss of visual sharpness. AMD progresses through ...

Geographic Atrophy (GA) is an advanced form of age-related macular degeneration (AMD) that results in progressive and irreversible vision loss, particularly in older adults. It occurs due to the ...

Geographic atrophy (GA) is a condition that typically progresses slowly, with lesions expanding by about 1 square millimeter per year, leading to blind spots due to retinal deterioration. Treatment ...

Geographic atrophy (GA), the late stage of age-related macular degeneration (AMD), may lead to vision loss. Here’s what to expect as the condition progresses. About 1 million people in the United ...

While there is currently no cure for geographic atrophy, certain treatments, such as complement inhibitors, can help slow its progression by targeting immune system activity that damages the macula.

The earlier patients with potentially blinding geographic atrophy start treatment with the complement inhibitor pegcetacoplan, the more retinal tissue they retain 4 years later compared with patients ...

A novel outcome measure for geographic atrophy, the Geographic Atrophy Weighted-by-Acuity Index, aligned with best-corrected visual acuity, showing better correlation and predictive accuracy than the ...

The following slide deck was published by Annexon, Inc. in conjunction with this event.

What is IZERVAY™?IZERVAY (avacincaptad pegol intravitreal solution) is a prescription eye injection, used to treat geographic atrophy (GA), the advanced form of dry age-related macular degeneration ...

—Certain imaging biomarkers and demographic factors are associated with geographic atrophy growth rate and may guide the selection of patients for the use of newer therapeutics. As the population ...